BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.…
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell Therapeutics (NASDAQ: BCTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 31 employees.
The shares were at 3.060 USD on 20 November 2026, down 69.7% over 52 weeks. Its 52-week range is 2.600 USD to 13.09 USD: the price is 76.6% below the high and 17.7% above the low.
Its market capitalisation is 26.72M USD.
BriaCell Therapeutics reports return on equity of -212.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 20.54M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.